Employees: 156
Size Delcath Systems (DCTH) is a United States Health Care company (Medical Specialties) with a market value of $685M, the 2475th largest of 3,085 United States companies the cockpit tracks. Shares closed at $19.70 on 18 Nov 2026.
Performance Over six months the shares gained 75.4%, against -15.1% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 38.1% over the last twelve months (peer median +14.8%); the operating margin is 5.2% (peer median 15.6%).
Valuation It trades at 358.9× forward earnings against a peer median of 20.5× (most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 33% a year for seven years (Req g). Recent delivered growth is +120%, so the hurdle is -87 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.1 points above its cost of capital (8.1% WACC).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $110M | $85.2M | $37.2M | $2.06M | $2.72M |
| Revenue growth | — | +129% | +1,702% | -24% | — |
| Gross profit | $96.3M | $73.4M | $31.0M | $1.30M | $1.46M |
| EBITDA | $6.29M | $1.01M | -$12.2M | -$38.1M | -$33.3M |
| Net income | $6.65M | $2.70M | -$26.4M | -$47.7M | -$36.5M |
| Free cash flow | $20.1M | $21.0M | -$19.2M | -$31.3M | -$25.2M |
| Capital expenditure | $2.88M | $1.55M | $559,000 | $58,000 | $209,000 |
| Total debt | $2.41M | $936,000 | $1.04M | $11.0M | $17.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DCTH | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +33.5% | -8.9% | highest of 21 |
| 6-month return | +75.4% | -15.1% | 2nd highest of 21 |
| Distance from 52-week high | -12.5% | -35.5% | 3rd highest of 21 |
| Revenue growth (TTM) | +38.1% | +14.8% | 4th highest of 21 |
| Operating margin | 5.2% | 15.6% | 9th lowest of 21 |
| Forward P/E | 358.9× | 20.5× | most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 33.4% | 3.4% | most demanding of 17 |
| Growth delivered (Del g) | +120.2% | +12.9% | highest of 17 |
| Hurdle (Req g minus delivered) | -86.8 pp | -11.1 pp | least demanding of 17 |
| ROIC minus cost of capital | +6.1 pp | +3.8 pp | 9th highest of 21 |
| EV / EBITDA | 92.8× | 8.5× | most expensive of 7 |
| Net debt / EBITDA | -16.2× | -1.2× | least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Delcath Systems DCTH | United States | $685M | +75% | +38% | 5% | 358.9× | 33.4% | +120.2% |
| Livsmed 491000.KS | South Korea | $687M | -47% | +89% | -77% | n/a | n/a | n/a |
| Shenzhen Sunnypol Optoelectornics 002876.SZ | China | $680M | -9% | +29% | 5% | 39.0× | 10.1% | +14.2% |
| Shenzhen Lifotronic Technology 688389.SS | China | $692M | -14% | +14% | 13% | 29.9× | 11.6% | +13.3% |
| Shanghai Sanyou Medical 688085.SS | China | $692M | -23% | +15% | 4% | 50.0× | 29.0% | +6.8% |
| Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZ | China | $697M | +148% | -14% | 3% | n/a | 31.8% | -0.6% |
| Shanghai INT Medical Instruments 1501.HK | Hong Kong | $700M | -25% | +35% | 21% | 15.9× | -3.3% | +23.5% |
| Japan Lifeline 7575.T | Japan | $703M | +34% | +6% | 19% | 14.5× | -9.5% | +2.9% |
| SWS Hemodialysis Care 688410.SS | China | $706M | -11% | +31% | 19% | 23.5× | 16.2% | +25.9% |
| Shanghai Kinetic Medical 300326.SZ | China | $662M | -10% | -28% | 17% | 26.0× | 6.6% | -1.9% |
| Synektik SNT.WA | Poland | $662M | +10% | +32% | 24% | 13.8× | 0.2% | +47.5% |
| Doctorglasses Chain 300622.SZ | China | $710M | -22% | +6% | 14% | 22.8× | -3.4% | +15.7% |
| QuidelOrtho QDEL | United States | $657M | -20% | -5% | -2% | 10.7× | n/a | n/a |
| Caina Technology 301122.SZ | China | $721M | +36% | +61% | 0% | 55.4× | n/a | n/a |
| AK Medical 1789.HK | Hong Kong | $642M | -23% | +16% | 26% | 10.5× | -11.5% | +6.7% |
| Shanghai Aladdin Biochemical Technology 688179.SS | China | $736M | -37% | +39% | 24% | 27.4× | 17.1% | +24.2% |
| BMC Medical 301367.SZ | China | $737M | -17% | +37% | 17% | 18.7× | -1.5% | +15.6% |
| Beijing Aerospace Changfeng 600855.SS | China | $738M | -44% | -10% | -19% | n/a | n/a | n/a |
| InMode INMD | United States | $741M | -8% | +2% | 18% | 9.8× | -10.8% | +12.4% |
| Shanghai Runda Medical Technology 603108.SS | China | $744M | -36% | -12% | -2% | 20.5× | 20.3% | -0.2% |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $744M | -3% | +12% | 18% | 16.2× | -1.9% | +11.8% |